NCT04037254 2026-04-06
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
Clinical Trials
6 trialsNCT00936390 2026-03-06
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT00066690 2026-02-06
SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT00066703 2026-02-06
TEXT
ETOP IBCSG Partners Foundation
Phase 3 Completed